IceCure Medical Ltd ICCM
0.77 USD -0.05 (-6.31%)
Nov 10, 2026, 12:03 PM EST
0.76 Day range 0.84
0.65 52-week range 22.50
- YTD
- -95.79%
- 1 year
- -96.44%
News
benzinga.com IceCure Medical Receives New Patent In China For Covering A Connector Used In Its Cryogenic Technology Platform IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
benzinga.com IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer First patient enrolled and treated at West Cancer Center in Tennessee, USACAESAREA, Israel, Oct. 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients…- benzinga.com IceCure Medical Adds Legacy Health In Portland, Oregon, As New U.S. Clinical Site For Its Post-Marketing ChoICE Study Evaluating Prosense Cryoablation For Treatment Of Low-Risk Breast Cancer Adds Legacy Health in Portland, Oregon, with its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center , as a new U.S. clinical site for its post-marketing study (the "ChoICE…
benzinga.com Full Transcript: Icecure Medical Q2 2026 Earnings Call Icecure Medical (NASDAQ:ICCM) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For…- benzinga.com IceCure Medical Receives Approval From China's National Medical Products Administration For Its ProSense System, Associated Cryoprobes IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
benzinga.com IceCure Medical Inks Distribution Agreement With Scovas Medical To Distribute IceCure's ProSense Cryoablation Systems In Netherlands IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to- benzinga.com IceCure Medical Says JHM-IRB Of West Cancer Center & Research Institute In Germantown, Tennessee, Approves Post-Marketing Study For ProSense Cryoablation In Local Treatment Of Low-Risk Breast Cancer Patients are expected to enroll in the post-marketing study in the coming weeks, following approval from the Institutional Review Board of West Cancer Center & Research Institute in Germantown,…
- benzinga.com IceCure Medical Highlights Peer‑Reviewed Publications Reinforcing Cryoablation’s Growing Clinical Role In Breast Cancer Treatment De‑Escalation, Including FDA Authorization Of ProSense, Updated ASBrS Guidelines, And Positive ICE3 5‑Yr Outcomes New review by leading U.S. experts highlights ProSense® FDA marketing authorization, updated American Society of Breast Surgeons guidelines, and encouraging outcomes from the five-year ICE3 clinical…
- benzinga.com Icecure Medical Q2 EPS $(1.37) Beats $(1.40) Estimate, Sales $889.000K Miss $1.450M Estimate Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(1.37) per share which beat the analyst consensus estimate of $(1.40) by 2.14 percent. This is a 23.89 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
- benzinga.com IceCure Medical Announces That The Society Of Interventional Oncology Submitted A Petition To The National Comprehensive Cancer Network Breast Cancer Guidelines Panel To Include Percutaneous Cryoablation Without Surgical Excision As An Option For Breast Cancer IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers OSR Health (NASDAQ:OSRH) stock increased by 7.2% to $0.33 during Wednesday's after-market session. The company's market cap stands at $11.0 million. BioRestorative Therapies (NASDAQ:BRTX)…
benzinga.com IceCure Medical Notes Growing International Interest In Its ProSense System In Brazil Growing physician interest and commercial adoption for ProSense™ in Brazil's expanding interventional oncology markets increased following FDA authorizationIndependent study evaluating breast cancer…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 67.3% to $2.08 during Friday's regular session. The market value of their outstanding shares is at $2.2 million. The company's, Q1 earnings…
benzinga.com What's Going On With IceCure Medical Stock On Friday? IceCure Medical (NASDAQ: ICCM) has officially regained compliance with Nasdaq's minimum bid price requirement. Read the details.- benzinga.com IceCure Medical Regains Nasdaq Compliance IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's regular session. The market value of their outstanding shares is at $22.1 million. Icecure Medical…
benzinga.com KB Home Posts Upbeat Q2 Sales, Joins Inmode, Icon And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares jumped 16.2%. Other big gainers: WEN, ABSI, RUN, CCXI, ENRD, SFTX, ICCM, INMD, DFH.- benzinga.com IceCure Medical Highlights Newly Published Peer-Reviewed Journal Article Presenting Key Clinical Advantages Of Cryoablation Over Radiofrequency Ablation For Early-Stage Breast Cancer Published in the International Journal of Surgery, globally ranked in the top three among surgery journals, the article highlights strong clinical outcomes with ProSense® cryoablation and describes…
benzinga.com Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monday U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other gaining stocks include DFTX, HIVE, SSTK, BWIN, ICCM, ORKA, CHRN, UMC,…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.
benzinga.com Smartbird, Nebius Group, IceCure Medical, Robinhood And Meta: Why These 5 Stocks Are On Investors' Radars Today Major U.S. stock indexes closed lower on Wednesday, with the Dow Jones Industrial Average slipping 0.98% to 51,942.55.
benzinga.com IceCure Medical Commences ~$5.5M Offering Of Ordinary Shares, Pre-Funded Warrants At Combined Price Of $3/Share IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com IceCure Stock Surges After 70% ProSense Install Increase IceCure Medical shares are soaring Wednesday after reporting a 70% jump in U.S. installs of its ProSense breast cancer cryoablation system.
benzinga.com Crude Oil Edges Higher; US Retail Sales Top Estimates U.S. stocks up, Dow Jones gains 0.39%. NASDAQ rose 0.09%, S&P 500 up 0.11%. Industrials shares jump 0.9%, while communication services fall 1.7%.
benzinga.com US Stocks Edge Higher; CarMax Posts Upbeat Earnings US stocks gain in morning trading, Dow up 0.1%. Tech sector leads gains, while communication services fall. CarMax beats earnings expectations.
benzinga.com IceCure Medical Reports 70% Growth In U.S. ProSense Install Base Following FDA Clearance Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures rise, Nasdaq up 1%. Graham Corp shares down 8.7%. Other stocks declining in pre-market trading: BVC, TLK, INDP, APPN, WIX, KB, SSSS, IPSC, AMPL, ICCM, SBSW, ROMA.- benzinga.com IceCure Medical Announces 1-For-30 Reverse Share Split, Effective June 4, 2026 Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets StrategyCAESAREA, ISRAEL, June 2, 2026 /PRNewswire/ -- IceCure Medical Ltd. (the "Company" or "IceCure" or…
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com IceCure Medical Features Cryoablation And ProSense At Annual ECIO 2026 At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained…
- benzinga.com Maxim Group Maintains Buy on Icecure Medical, Lowers Price Target to $1 Maxim Group analyst Anthony Vendetti maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from $3 to $1.
benzinga.com Icecure Medical Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $911.000K Miss $1.344M Estimate Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is unchanged from the same period last year.…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com IceCure Medical Reports Preliminary Q1 ProSense U.S. Sales Up 30% YoY The performance in the U.S. represents the adoption of ProSense® immediately following the U.S. Food and Drug Administration's ("FDA") clearance of ProSense® for the local treatment of low-risk…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com IceCure Reports 4-Year ICESECRET Results, With ProSense Showing Up To 89.4% Recurrence-Free Rates In Kidney Cancer Study At a median follow-up of four years, 89.4% recurrence-free rate in patients with tumors ≤3 cm and no prior kidney cancer; 83.9% recurrence-free rate for general study populationFull analysis of…
- benzinga.com IceCure Appoints Meir Peleg As CFO, Effective May 17, 2026 Meir Peleg brings over 20 years of financial leadership and experience including with Nasdaq listed companies IceCure intends to appoint Dr. Richard Fine as Medical Director
- benzinga.com Icecure Medical Q4 EPS $(0.06) Misses $(0.04) Estimate, Sales $1.279M Miss $1.900M Estimate Icecure Medical (NASDAQ:ICCM) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.04) by 33.33 percent. This is a 25 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 17, 2026